Literature DB >> 27986831

Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance.

Róbert Wagner1,2,3, Liisa H Hakaste4, Emma Ahlqvist5, Martin Heni1,2,3, Jürgen Machann2,3,6, Fritz Schick6, Emmanuel Van Obberghen7, Norbert Stefan1,2,3, Baptist Gallwitz1,2, Tiinamaija Tuomi4,8, Hans-Ulrich Häring1,2,3, Leif Groop5,9, Andreas Fritsche10,2,3.   

Abstract

Glucagon levels are classically suppressed after glucose challenge. It is still not clear as to whether a lack of suppression contributes to hyperglycemia and thus to the development of diabetes. We investigated the association of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon levels are observed in subjects with impaired glucose tolerance (IGT). Glucagon levels were measured during OGTT in a total of 4,194 individuals without diabetes in three large European cohorts. Longitudinal changes in glucagon suppression were investigated in 50 participants undergoing a lifestyle intervention. Only 66-79% of participants showed suppression of glucagon at 120 min (fold change glucagon120/0 <1) during OGTT, whereas 21-34% presented with increasing glucagon levels (fold change glucagon120/0 ≥1). Participants with nonsuppressed glucagon120 had a lower risk of IGT in all cohorts (odds ratio 0.44-0.53, P < 0.01). They were also leaner and more insulin sensitive and had lower liver fat contents. In the longitudinal study, an increase of fold change glucagon120/0 was associated with an improvement in insulin sensitivity (P = 0.003). We characterize nonsuppressed glucagon120 during the OGTT. Lower glucagon suppression after oral glucose administration is associated with a metabolically healthier phenotype, suggesting that it is not an adverse phenomenon.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27986831     DOI: 10.2337/db16-0354

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health.

Authors:  Robert Wagner; Sabine S Eckstein; Louise Fritsche; Katsiaryna Prystupa; Sebastian Hörber; Hans-Ulrich Häring; Andreas L Birkenfeld; Andreas Peter; Andreas Fritsche; Martin Heni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.

Authors:  Xi Chen; Enrique Maldonado; Ralph A DeFronzo; Devjit Tripathy
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

3.  Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations.

Authors:  Anna-Maria Ordelheide; Anja Böhm; Daniela Kempe-Teufel; Robert Wagner; Fausto Machicao; Martin Heni; Norbert Stefan; Andreas Fritsche; Hans-Ulrich Häring; Harald Staiger
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

4.  Reduced somatostatin signalling leads to hypersecretion of glucagon in mice fed a high-fat diet.

Authors:  Joely A Kellard; Nils J G Rorsman; Thomas G Hill; Sarah L Armour; Martijn van de Bunt; Patrik Rorsman; Jakob G Knudsen; Linford J B Briant
Journal:  Mol Metab       Date:  2020-05-21       Impact factor: 7.422

5.  Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test.

Authors:  Micaela Morettini; Laura Burattini; Christian Göbl; Giovanni Pacini; Bo Ahrén; Andrea Tura
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

6.  Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion.

Authors:  Corinna Dannecker; Robert Wagner; Andreas Peter; Julia Hummel; Andreas Vosseler; Hans-Ulrich Häring; Andreas Fritsche; Andreas L Birkenfeld; Norbert Stefan; Martin Heni
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.